RPG Life Sciences enters cardio-vascular segment with introduction of Impulse
17 Aug 2010
RPG Group's phrmaceuticals arm, RPG Life Sciences, has launched its third product vertical, Impulse, in the growing cardio-metabolic segment, after its earlier introductio of of Empathy, a neuropsychiatry product and Neolife in the oncology segment last month.
RPGLS is ranked 39th amongst the pharma companies focusing on the cardiovascular segment in India, with brands like Aldactone and Spiromide.
RPG Life Sciences aims to emerge among the top 20 companies in cardiovascular therapy segment in India by 2015.
It plans to ahieve this by launching new products to cater to various therapeutic needs in tyhe cardio-metabolic segment and aggressive marketing strategies.
RPG Life Sciences is present in formulations, bulk drugs and biotech businesses and has presence in Europe, Latin America, Africa, Canada and the South East Asian countries, apart rom its presence in India.
